TNF-alpha inhibitors:
- Adalimumab (Humira)
- Certolizumab pegol (Cimzia)
- Etanercept (Enbrel)
- Infliximab (Remicade)
IL-23 inhibitors:
- Guselkumab (Tremfya)
- Tildrakizumab (Ilumya)
- Risankizumab (Skyrizi)
IL-17A inhibitors:
- Ixekizumab (Taltz)
- Secukinumab (Cosentyx)
IL-12/IL-23 inhibitors:
- Ustekinumab (Stelara)
IL-17RA inhibitors:
- Brodalumab (Siliq)
Biologics, also known as biologic therapies, are a class of medications that are designed to target specific molecules or cells within the immune system in order to treat various diseases, including psoriasis. There are several different types of biologics available, each of which works by targeting a different part of the immune system.
TNF-alpha inhibitors are a class of biologics that target the protein TNF-alpha (tumor necrosis factor-alpha). TNF-alpha is a pro-inflammatory cytokine that is involved in the development of psoriasis and other autoimmune diseases. By binding to and neutralizing TNF-alpha, TNF-alpha inhibitors are able to reduce inflammation and improve symptoms of psoriasis. Examples of TNF-alpha inhibitors include Adalimumab (Humira), Certolizumab pegol (Cimzia), Etanercept (Enbrel), and Infliximab (Remicade).
IL-23 inhibitors are another class of biologics that are used to treat psoriasis. These medications target the IL-23 (interleukin-23) cytokine, which is a pro-inflammatory protein that plays a critical role in the development of psoriasis. By binding to and inhibiting IL-23, these medications are able to reduce inflammation and improve symptoms of psoriasis. Examples of IL-23 inhibitors include Guselkumab (Tremfya), Tildrakizumab (Ilumya) and Risankizumab (Skyrizi)
IL-17A inhibitors are a class of biologics that target the IL-17A (interleukin-17A) protein, a pro-inflammatory cytokine that plays a key role in the development of psoriasis. By binding to and inhibiting IL-17A, these medications are able to reduce inflammation and improve symptoms of psoriasis. Examples of IL-17A inhibitors include Ixekizumab (Taltz) and Secukinumab (Cosentyx).
IL-12/IL-23 inhibitors are a class of biologics that target the IL-12 and IL-23 cytokines, both of which are pro-inflammatory proteins that play a key role in the development of psoriasis. By binding to and inhibiting IL-12 and IL-23, these medications are able to reduce inflammation and improve symptoms of psoriasis. An example of IL-12/IL-23 inhibitors is Ustekinumab (Stelara).
IL-17RA inhibitors are a class of biologics that targets the IL-17RA (interleukin-17 receptor A) protein, a pro-inflammatory protein that plays a key role in the development of psoriasis. By binding to and inhibiting IL-17RA, these medications are able to reduce inflammation and improve symptoms of psoriasis. An example of IL-17RA inhibitors is Brodalumab (Siliq).
In conclusion, biologics are a powerful class of medications that are used to treat psoriasis by targeting specific molecules or cells within the immune system. TNF-alpha inhibitors, IL-23 inhibitors, IL-17A inhibitors, IL-12/IL-23 inhibitors, and IL-17RA inhibitors are all types of biologics that are used to treat psoriasis by targeting different parts of the immune system. These medications have been shown to be effective in reducing inflammation and improving symptoms of psoriasis, but they must be used under the guidance of a healthcare professional.
Comments
Post a Comment